Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential

Intellia Therapeutics is closing out the week strong, reporting good news for a duo of gene editing trials. Both are early-stage, but the company is already prepping to move the transthyretin (ATTR) amyloidosis therapy, NTLA-2001, into what it hopes will be a pivotal study.